- Conditions
- PTSD
- Interventions
- MDMA, Psychotherapy
- Drug · Behavioral
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 30
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Facioscapulohumeral Muscular Dystrophy
- Interventions
- EPI-321
- Biological
- Lead sponsor
- Epicrispr Biotechnologies, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 2 more
- Conditions
- Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma
- Interventions
- Azacitidine, Entinostat, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Tampa, Florida • Annapolis, Maryland + 4 more
- Conditions
- T-cell Lymphoma, Aggressive B-cell Lymphoma, Non-Hodgkin's Lymphomas, Indolent B-cell Lymphoma
- Interventions
- Decitabine, Tetrahydrouridine
- Drug
- Lead sponsor
- Yogen Saunthararajah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Lung Cancer, Non-small Cell Lung Cancer
- Interventions
- Nivolumab, oral decitabine, Tetrahydrouridine
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Cleveland, Ohio
- Conditions
- Pancreatic Cancer
- Interventions
- oral azacitidine, Observation
- Drug · Other
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
- Conditions
- Hepatitis C, HIV
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Small Cell Lung Cancer, Large Cell Neuroendocrine (NE) Tumors, Treatment Failure, Biomarkers / Blood, Biomarkers, Immunotherapy
- Interventions
- Carboplatin/Cisplatin -Etoposide - Atezolizumab
- Drug
- Lead sponsor
- Oncology Center of Biochemical Education And Research
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
- Interventions
- Azacitidine, MGCD0103
- Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Non-Small Cell Lung Cancer, Epigenetic Therapy
- Interventions
- Azacitidine, Entinostat, Nivolumab, CC-486 300
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Baltimore, Maryland + 1 more
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
- Interventions
- Pembrolizumab, Tamoxifen, Vorinostat
- Biological · Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- BPH (Benign Prostatic Hyperplasia), Lower Urinary Track Symptoms
- Interventions
- raloxifene, Finasteride
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Metastatic Melanoma, Melanoma, BRAF-mutated Metastatic Melanoma, V600EBRAF-mutated Metastatic Melanoma
- Interventions
- Vemurafenib + Cobimetinib, Decitabine
- Drug
- Lead sponsor
- Mohammed M Milhem
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Adult Brain Tumor, Lung Cancer, Radiation Toxicity
- Interventions
- laboratory biomarker analysis
- Other
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2025
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Not interventional
- Other
- Lead sponsor
- New Mexico Cancer Research Alliance
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2023
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Aging
- Interventions
- Sham, Therapeutic Plasma Exchange, IVIG
- Device · Drug
- Lead sponsor
- Dobri Kiprov
- Industry
- Eligibility
- 50 Years to 95 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Mill Valley, California
- Conditions
- Open Angle Glaucoma (OAG), NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)
- Interventions
- ER-100 epigenetic therapy
- Genetic
- Lead sponsor
- Life Biosciences Inc.
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 4
- States / cities
- Glendale, California • Boston, Massachusetts • New York, New York + 1 more
- Conditions
- Major Depressive Disorder, Suicidal Ideation
- Interventions
- paliperidone, lithium, Placebo
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years to 65 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Aging
- Interventions
- Hyperbaric Oxygen Therapy
- Procedure
- Lead sponsor
- TruDiagnostic
- Industry
- Eligibility
- 40 Years to 70 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Florham Park, New Jersey
- Conditions
- Urothelial Carcinoma
- Interventions
- Atezolizumab, Guadecitabine
- Drug
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Baltimore, Maryland • Philadelphia, Pennsylvania
- Conditions
- High-risk Prostate Cancer
- Interventions
- Neoadjuvant Epigenetic Therapy
- Drug
- Lead sponsor
- Edwin Posadas, MD
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood
- Interventions
- Azacytidine, Fludarabine, Cytarabine, Intrathecal (IT) Cytarabine, Intrathecal Methotrexate (IT MTX)
- Drug
- Lead sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 19
- States / cities
- Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 16 more
- Conditions
- Childhood Cancer
- Interventions
- One-time blood draw, Evaluation of CpG methylation, Metabolomic analysis
- Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Breast Neoplasms
- Interventions
- Tamoxifen, Vorinostat, Pembrolizumab
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- San Francisco, California